SCHEMBL3685360

SCHEMBL3685360

CCCC[C@H](C(=O)O)n1c(=O)c2ccccc2n(C(C)c2c[nH]c3cccc(C)c23)c1=O

nearest known ligand 0.48

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CMA1 P23946 9/20 0.48
▸ FFAR1 O14842 1/20 0.34
▸ GPR84 Q9NQS5 1/20 0.34
▸ CNR2 P34972 4/20 0.34
▸ CNR1 P21554 3/20 0.34
▸ POLB P06746 1/20 0.34
▸ DNMT1 P26358 1/20 0.33
▸ ITGB2 P05107 1/20 0.33
▸ ICAM1 P05362 1/20 0.33
▸ ITGAL P20701 1/20 0.33
▸ MGAM O43451 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ SI P14410 1/20 0.33
▸ MGAM2 Q2M2H8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3682510 1.00 CMA1 (0.48) CMA1FFAR1GPR84CNR2CNR1
SCHEMBL3688465 1.00 CMA1 (0.48) CMA1FFAR1GPR84CNR2CNR1
SCHEMBL3681842 0.95 CMA1 (0.47) CMA1FFAR1GPR84POLBDNMT1
SCHEMBL3681840 0.95 CMA1 (0.47) CMA1FFAR1GPR84POLBDNMT1
SCHEMBL3699285 0.95 CMA1 (0.47) CMA1FFAR1GPR84POLBDNMT1
SCHEMBL3688507 0.91 POLB (0.42) CMA1GPR84POLBDNMT1ITGB2
SCHEMBL3688934 0.91 POLB (0.42) CMA1GPR84POLBDNMT1ITGB2
SCHEMBL3685767 0.91 POLB (0.42) CMA1GPR84POLBDNMT1ITGB2
SCHEMBL3690976 0.91 CMA1 (0.43) CMA1FFAR1GPR84CNR2CNR1
SCHEMBL3690973 0.91 CMA1 (0.43) CMA1FFAR1GPR84CNR2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188277-B1 QUINAZOLINEDIONE CHYMASE INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2012-11-21 — — EP claimed
EP-2188277-A1 QUINAZOLINEDIONE CHYMASE INHIBITORS Boehringer Ingelheim International GmbH (DE) 2010-05-26 — — EP claimed
WO-2009023655-A1 QUINAZOLINEDIONE CHYMASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-02-19 — — WO claimed
US-8377949-B2 Quinazolinedione chymase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-02-19 — — US disclosed
EP-2188277-B1 QUINAZOLINEDIONE CHYMASE INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2012-11-21 — — EP disclosed
US-20120122863-A1 Quinazolinedione Chymase Inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-17 — — US disclosed
EP-2188277-A1 QUINAZOLINEDIONE CHYMASE INHIBITORS Boehringer Ingelheim International GmbH (DE) 2010-05-26 — — EP disclosed
WO-2009023655-A1 QUINAZOLINEDIONE CHYMASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-02-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122863-A1 Quinazolinedione Chymase Inhibitors CMA1, CTSC, TPSG1 CMA1 1/4885FFAR1 2510/4885GPR84 371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback